Implementation of the first respiratory syncytial (RSV) immunization campaign with nirsevimab in an autonomous community in Spain

References

• Calvo C, Pozo F, García-García ML, Sanchez M, Lopez‐Valero M, Pérez‐Breña P, Casas I. Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three-year prospective study. Acta Paediatr. 2010;99(6):883–9. doi:10.1111/j.1651-2227.2010.01714.x.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. doi:10.1016/S0140-6736(22)00478-0.
   PubMed Web of Science ®Google Scholar
• Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, Van de Ven PM, Snape MD, Drysdale SB, Pollard AJ, Robinson H. et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2022;S2213-2600(22):00414–3.
   Google Scholar
• Riccio MD, Spreeuwenberg P, Osei-Yeboah R, Johannesen CK, Fernandez LV, Teirlinck AC, Wang X, Heikkinen T, Bangert M, Caini S. et al. Burden of respiratory syncytial virus in the European Union: estimation of RSV-associated hospitalizations in children under 5 years. J Infect Dis. 2023;228(11):1528–38. doi:10.1093/infdis/jiad188.
   Web of Science ®Google Scholar
• Grupo de Trabajo utilización de nirsevimab frente a infección por virus respiratorio sincitial de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, julio 2023. Recomendaciones de utilización de nirsevimab frente a virus respiratorio sincitial para la temporada 2023-2024. [cited 2024 Jan 2]. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/Nirsevimab.pdf.
   Google Scholar
• European Medicines Agency (EMA). Beyfortus® (nirsevimab) - European Public Assessment Report (EPAR). Procedure No. EMEA/H/C/005304/0000.[cited 2024 Jan 4]. https://www.ema.europa.eu/en/documents/assessment-report/beyfortus-epar-publicassessment-report_en.pdf.
   Google Scholar
• Drysdake SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT. et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425–35. doi:10.1056/NEJMoa2309189.
   Web of Science ®Google Scholar
• López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, Carballido-Fernández M, Pineda-Caplliure A, Mollar-Maseres J, Shalabi Benavent M. et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. ro Surveill. 2024;29(6):2400046. doi:10.2807/1560-7917.ES.2024.29.6.2400046.
   Google Scholar
• Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, Del Lero N, Schalbar C, Do Carmo E, Kohnen M. et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29(4). doi:10.2807/1560-7917.ES.2024.29.4.2400033.
   Google Scholar
• Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018;37(9):886–92. doi:10.1097/INF.0000000000001916.
   PubMed Web of Science ®Google Scholar
• Sánchez-Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B. et al. Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev. 2020;33:35–44. doi:10.1016/j.prrv.2018.12.001.
   Web of Science ®Google Scholar
• Figueras Aloy J, Carbonell Estrany X. Comité de Estándares de la SENeo. Update of recommendations on the use of palivizumab as prophylaxis in RSV infections. An Pediatr (Barc). 2015 Mar. 82(3):199.e1–2. doi:10.1016/j.anpedi.2014.10.004.
   Google Scholar
• Cifras oficiales de población de los municipios españoles en apliación de la Ley de Bases del Régimen Local. Art. 17. Instituto Nacional de Estadística (INE); 2023 [cited 2024 Jan 15]. https://www.ine.es/dynt3/inebase/es/index.htm?padre=525.
   Google Scholar
• Movimiento Natural de la Población: Nacimientos. Instituto Nacional de Estadística (INE). 2022 [cited 2024 Jan 15]. https://www.ine.es/jaxiT3/Datos.htm?t=6518.
   Google Scholar
• Ezpeleta G, Navascués A, Natividad Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, Muruzábal JC, García-Cenoz M, Trobajo-Sanmartín C, Echeverria A. et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: A population-based cohort study. Vaccines (Basel). 2024;12(4):383. doi:10.3390/vaccines12040383.
   Web of Science ®Google Scholar
• Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós M-T, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L. et al. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024; S1473–3099(24)00215–9. doi:10.1016/S1473-3099(24)00215-9.
   Google Scholar
• Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R. et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus-associated hospitalization among infants entering their first respiratory syncytial virus season - New vaccine surveillance network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024;73(9):209–14.
   Web of Science ®Google Scholar
• Infovac-France. Bulletin n°8 Août - Spécial Nirsevimab et Beyfortus: 2023 [cited 2024 Mar 13]. https://www.infovac.fr/actualites/bulletin-n-8-aout-special-nirsevimab-et-beyfortus.
   Google Scholar
• Centers for Disease Control and Prevention. RSV in Infants and Young Children. 2023 [cited 2024 Mar 13]. https://www.cdc.gov/rsv/high-risk/infants-young-children.html#:~:text=RSV%20antibody%20immunization%20is%20recommended,also%20get%20an%20RSV%20antibody.
   Google Scholar
• Centers for Disease Control and Prevention. Nirsevimab Receipt and Intent for Infants, U.S. 2024 [cited 2024 Mar 16]. https://www.cdc.gov/vaccines/imz-managers/coverage/rsvvaxview/nirsevimab-coverage.html.
   Google Scholar
• Centers for Disease Control and Prevention. Respiratory Syncytial Virus (RSV) Vaccination Coverage, Pregnant Persons. United States; 2024 [cited 2024 Mar 16]. https://www.cdc.gov/vaccines/imz-managers/coverage/rsvvaxview/nirsevimab-coverage.html.
   Google Scholar
• Centers for Disease Control and Prevention. RSV in Infants and Young Children. 2023 [cited 2024 Mar 16]. https://www.cdc.gov/rsv/high-risk/infants-young-children.html#:~:text=RSV%20antibody%20immunization%20is%20recommended,also%20get%20an%20RSV%20antibody.
   Google Scholar
• Lee Mortensen G, Harrod-Lui K. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies. Expert Rev Vaccines. 2022;21(10):1523–31. doi:10.1080/14760584.2022.2108799.
   PubMed Web of Science ®Google Scholar
• Congedo G, Lombardi GS, Zjalic D, Di Russo M, La Gatta E, Regazzi L, Indolfi G, Staiano A, Cadeddu C. Knowledge, attitudes and behaviours of a sample of Italian paediatricians towards RSV and its preventive strategies: a cross-sectional study. Ital J Pediatr. 2024;50(1):35. doi:10.1186/s13052-024-01593-1.
   Web of Science ®Google Scholar
• Community preventive services task force. Recommendation for use of immunization information systems to increase vaccination rates. J Public Health Manag Pract. 2015;21(3):249–. doi:10.1097/PHH.0000000000000092.
   PubMed Web of Science ®Google Scholar
• Poethko-Müller C, Ellert U, Kuhnert R, Neuhauser H, Schlaud M, Schenk L. Vaccination coverage against measles in German-born and foreign-born children and identification of unvaccinated subgroups in Germany. Vaccine. 2009;27(19):2563–9. doi:10.1016/j.vaccine.2009.02.009.
   PubMed Web of Science ®Google Scholar
• Fabiani M, Fano V, Spadea T, Piovesan C, Bianconi E, Rusciani R, Salamina G, Greco G, Ramigni M, Declich S. et al. Comparison of early childhood vaccination coverage and timeliness between children born to Italian women and those born to foreign women residing in Italy: A multi-centre retrospective cohort study. Vaccine. 2019;37(16):2179–87. doi:10.1016/j.vaccine.2019.03.023.
   PubMed Web of Science ®Google Scholar
• Pérez-Martín J, Bernal-González PJ, Jiménez-Guillén P, Fernández-Sáez L, Navarro-Alonso JA. Resultados de dos estrategias de captación en la vacunación frente al Virus del PapilomaHumano (VPH) en la Región de Murcia. 2010 [cited 2024 Mar 17]. https://sms.carm.es/ricsmur/bitstream/handle/123456789/2321/bem.2010.30.735.pdf?sequence=2&isAllowed=.
   Google Scholar
• euronews.health. Internet]. Lauren Chadwick; c2023 2024 Mar 17]. https://www.euronews.com/health/2023/10/29/stressed-and-very-angry-parents-struggle-to-get-doses-of-new-preventive-rsv-antibody-for-b.
   Google Scholar
• biopharmadive.com [Internet]. Delilah Alvarado; c2023 [cited 2024 Mar 17]. https://www.biopharmadive.com/news/sanofi-beyfortus-rsv-antibody-shortage/697731/.
   Google Scholar